Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors.

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation - 1 Sept 1995

Baker R

Abstract excerpt

New data presented at the Fourth HIV Drug Resistance Workshop in Italy suggest that treatment with Invirase (saquinavir) does not cause cross-resistance to other protease inhibitors, including Merck, Abbott, and Vertex compounds. In addition, HIV resistance to Invirase develops at a slower rate than seen with all other anti-HIV drugs, even after prolonged combination therapy with Invirase plus AZT. Data indicate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Isoquinolines

Share to Mutation

Share to Quinolines

Share to Saquinavir

Source

Identifiers

PMID: 11362895

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors.PMID 11362895Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.Semantic proximity Read ↗

Protease inhibitors: drug resistance and cross resistance overview.Semantic proximity Read ↗

Study: new drug doesn't display cross-resistance.Semantic proximity Read ↗

Conference highlight.Semantic proximity Read ↗

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.Semantic proximity Read ↗

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.Semantic proximity Read ↗

Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.Semantic proximity Read ↗

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.Semantic proximity Read ↗

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.Semantic proximity Read ↗

Telaprevir to boceprevir switch highlights lack of cross-reactivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.